Infectious Diseases in Critical Care Medicine

(ff) #1

monotherapy for cSSTI and intra-abdominal infections. There are also concerns about
emerging resistance.
Colistin use is seeing a reemergence as ICUs battle increasingly resistantAcinetobacter
andPseudomonas. Its utility is limited by its significant risk of nephrotoxicity.


ANTIBIOTIC CYCLING
We will make only brief mention of the concept of antibiotic cycling, since this practice
continues to be of unproven merit at the time of this writing. Antibiotic cycling involves
rotating the standard empiric therapy regimens in an ICU, usually every several months, with
the aim of reducing the emergence of drug-resistant pathogens. Several studies conducted
around the turn of the 21st century suggested great promise to this approach. In 2001,
Raymond and colleagues reported that rotating empiric regimens even at one-year intervals
might be beneficial (37). However, questions remained, and it was currently felt that the
evidence is insufficient to recommend this practice as a routine measure (8,38).


SUMMARY
In light of the continuous evolution of drug-resistant and MDR pathogens, limited numbers of
anti-infectives in the pipeline, and an increasing severity of illness among the ICU patient
population, special attention toward appropriate antibiotic selection is of utmost importance.
As we discussed in this chapter, prompt empirical therapy based on host factors and local
epidemiological data reduces morbidity and mortality; however, clinicians must be mindful
that their duty as stewards of our antimicrobial armamentarium does not end with the initial
selection. Providers must reassess antibiotic regimens on a regular basis for early de-escalation
to definitive therapy, dose optimization, compatibilities, untoward drug events, intravenous to
oral conversions, and importantly, therapy duration.


REFERENCES



  1. Rockeymoore MB, Holzmueller CG, Milstein A, et al. Updating the leapfrog group intensive care unit
    physician staffing standard. J Clin Outcomes Manage 2003; 10:31–37.

  2. Bryan CS. The role of the infectious diseases physician in setting guidelines for antimicrobial use. Bull
    N Y Acad Med 1987; 63:627–637.

  3. Dellit TH, Owens RC, McGowan JE Jr., et al. Infectious Diseases Society of America and the Society for
    Healthcare Epidemiology of America guidelines for developing an institutional program to enhance
    antimicrobial stewardship. Clin Infect Dis 2007; 44:159–177.

  4. Lautenbach E, Polk RE. Resistant gram-negative bacilli: a neglected healthcare crisis? Am J Health
    Syst Pharm 2007; 64(suppl 14):S3–S21.

  5. Shane R. CPOE: the science and the art. Am J Health Syst Pharm 2003; 60:1273–1276.

  6. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor
    for hospital mortality among critically ill patients. Chest 1999; 115:462–474.

  7. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for
    hospitalized patients. Clin Infect Dis 2000; 31(suppl 4):S131–S138.

  8. Derenski S. Principles of antibiotic therapy in severe infections: optimizing the therapeutic approach
    by use of laboratory and clinical data. Clin Infect Dis 2007; 45:S177–S183.

  9. Garnacho-Montero J, Ortiz-Leyba C, Herrera-Melero I, et al. Mortality and morbidity attributable to
    inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: a matched
    cohort study. J Antimicrob Chemother 2008; 61:436–441.

  10. Meybeck A, Ricard JD, Barnaud G, et al. Incidence and impact on clinical outcome of infections with
    piperacillin/tazobactam resistant Escherichia coli in ICU: a retrospective study. BMC Infect Dis 2008;
    8:67.

  11. Erlandsson M, Burman LG, Cars O, et al. Prescription of antibiotic agents in Swedish intensive care
    units is empiric and precise. Scand J Infect Dis 2007; 39:63–69.

  12. MacArthur RD, Miller M, Albertson T, et al. Adequacy of early empiric antibiotic treatment and
    survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis 2004; 38:284–288.

  13. American Thoracic Society. Infectious Diseases Society of America. Guidelines for the management of
    adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J
    Respir Crit Care Med 2005; 171:388–416.

  14. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial pneumonia in intensive care units
    in Europe (EPIC). JAMA 1995; 274:639–644.


Selection of Antibiotics in Critical Care 495

Free download pdf